NICE recommends Xarelto® as a treatment option for reducing secondary events in ACS

The National Institute for Health and Care Excellence (NICE) issued its Final Appraisal Determination (FAD) recommending Xarelto 2.5mg twice daily as an effective treatment option for preventing secondary events – such as death, heart attack or stroke – following acute coronary syndrome (ACS) in patients with elevated cardiac biomarkers, without prior stroke or transient ischaemic attack (TIA). (1) The FAD is the final phase in a multi-step review process by NICE and recognises the improved patient outcomes using Xarelto as a treatment option on top of dual antiplatelet therapy;* publication of guidance is expected to follow in Q1 2015.
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Tags: *** Editor's Pick Clinical trials Practical therapeutics Cost effectiveness Industry News Cardiovascular medicine Legislation & regulation Patient care acs antiplatelet therapy ATLAS ACS 2 TIMI 51 Latest News TIA Xaltero Source Type: news